azitra, inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. the company was founded in 2014 by scientists from yale university and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. for more information visit www.azitrainc.com.
Company profile
Ticker
AZTR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Azitra Inc
SEC CIK
Corporate docs
IRS number
464478536
AZTR stock data
Latest filings (excl ownership)
8-K
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
424B5
Prospectus supplement for primary offering
15 Feb 24
8-K
Azitra, Inc. Announces Pricing of Public Offering
14 Feb 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
FWP
Free writing prospectus
19 Jan 24
S-1
IPO registration
19 Jan 24
UPLOAD
Letter from SEC
11 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.40 mm | 4.40 mm | 4.40 mm | |||
Cash burn (monthly) | 630.01 k | 664.58 k | 28.24 k | |||
Cash used (since last report) | 4.30 mm | 4.53 mm | 192.56 k | |||
Cash remaining | 104.17 k | -131.55 k | 4.21 mm | |||
Runway (months of cash) | 0.2 | -0.2 | 149.0 |
Institutional ownership, Q2 2023
23.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 4 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 377.74 mm |
Total shares | 6.89 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bios Equity Partners | 6.80 mm | $33.32 mm |
Precept Management | 50.00 k | $182.00 mm |
Warberg Asset Management | 29.00 k | $105.56 mm |
Citadel Advisors | 15.62 k | $56.86 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Norm Staskey | Common Stock | Buy | Acquire P | No | No | 0.2108 | 47,600 | 10.03 k | 51,100 |
13 Feb 24 | Travis Whitfill | Common Stock | Buy | Acquire P | No | No | 0.3 | 15,000 | 4.50 k | 334,500 |
13 Feb 24 | Norm Staskey | Common Stock | Buy | Acquire P | No | No | 0.3 | 3,300 | 990.00 | 3,500 |
13 Feb 24 | Francisco D. Salva | Common Stock | Buy | Acquire P | No | No | 0.3 | 333,300 | 99.99 k | 338,300 |
8 Sep 23 | Norm Staskey | Stock Options Common Stock | Grant | Acquire A | No | No | 2.07 | 10,000 | 20.70 k | 10,000 |
News
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
2 Apr 24
Azitra, Inc. Announces FY23 EPS $(1.83) Vs $(12.74) YoY; Revenue $686K Vs $284K YoY
15 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
14 Feb 24